Sardocor

Executive Summary

Sardocor is a clinical-stage biotechnology company pioneering cardiac gene therapy for common and rare cardiac diseases. Founded in 2020 and headquartered in San Diego, the company leverages a proprietary delivery platform to develop next-generation gene therapies. Sardocor's approach aims to address the underlying genetic causes of cardiac conditions, potentially offering disease-modifying treatments for patients with high unmet medical need. The company's initial focus is on shortening the regulatory pathway for effective gene therapies, which could accelerate time-to-market and potentially capture a significant share of the cardiac gene therapy market. Sardocor is advancing its lead candidate toward clinical trials and is expected to initiate a Phase 1/2 study in the near term. The company's scientific founders bring deep expertise in cardiac biology and gene therapy, positioning Sardocor to overcome historical challenges in cardiac gene delivery. While still in early stages, the platform's versatility may enable expansion into multiple indications. Key upcoming milestones include IND clearance, trial initiation, and initial proof-of-concept data. Sardocor's progress will be closely watched given the substantial unmet need in cardiac diseases and the potential for gene therapy to transform treatment paradigms.

Upcoming Catalysts (preview)

• Q2 2026FDA IND clearance for lead gene therapy candidate75% success
• Q3 2026Initiation of Phase 1/2 clinical trial for lead candidate70% success
• Q4 2026Presentation of preclinical data at major cardiology conference85% success